$KPRX
KIORA PHARMACEUTICALS INC Stock $kprx

$kprx Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-K Financial Statement

#000114420417010635 Filed on February 23, 2017

Income Statement

Concept	2016 Q4	2016	2015 Q4
Revenue	$160.0K	$669.3K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.280M	$5.594M	$1.290M
YoY Change	-0.78%	41.25%	360.71%
% of Gross Profit
Research & Development	$2.580M	$8.423M	$1.380M
YoY Change	86.96%	209.98%	1154.55%
% of Gross Profit
Depreciation & Amortization	$10.00K	$5.185K	$0.00
YoY Change		312.49%
% of Gross Profit
Operating Expenses	$3.860M	$14.02M	$2.680M
YoY Change	44.03%	109.9%	587.18%
Operating Profit
YoY Change
Interest Expense	$0.00	$275.00	-$10.00K
YoY Change	-100.0%	-99.99%	-125.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	$3.409K	$0.00
YoY Change		-100.2%
Pretax Income	-$3.700M	-$13.34M	-$2.690M
YoY Change	37.55%	52.41%	668.57%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$3.700M	-$13.34M	-$2.690M
YoY Change	37.55%	59.08%	540.48%
Net Earnings / Revenue	-2312.5%	-1993.76%
Basic Earnings Per Share
Diluted Earnings Per Share	-$185.00	-$22.66M	-$269.00
COMMON SHARES
Basic Shares Outstanding	9.586M shares		7.655M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.640M	$3.635M	$8.390M
YoY Change	-56.62%	-56.67%	4835.29%
Cash & Equivalents	$3.680M	$3.635M	$8.394M
Short-Term Investments
Other Short-Term Assets	$460.0K	$465.0K	$120.0K
YoY Change	283.33%	287.48%	300.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$37.35K		$907.5K
Total Short-Term Assets	$4.154M	$4.154M	$9.449M
YoY Change	-56.04%	-56.04%	4219.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$38.04K	$38.04K	$0.00
YoY Change			-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$55.31K	$100.3K	$38.59K
YoY Change	43.35%	67.18%	3.07%
Total Long-Term Assets	$5.577M	$5.577M	$58.59K
YoY Change	9418.43%	9194.27%	-95.08%
TOTAL ASSETS
Total Short-Term Assets	$4.154M	$4.154M	$9.449M
Total Long-Term Assets	$5.577M	$5.577M	$58.59K
Total Assets	$9.731M	$9.731M	$9.508M
YoY Change	2.34%	2.32%	574.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.412M	$1.412M	$417.7K
YoY Change	238.07%	236.22%	-26.2%
Accrued Expenses	$1.671M	$1.671M	$1.096M
YoY Change	52.49%	51.9%	20.01%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.308M	$7.308M	$3.421M
YoY Change	113.63%	113.69%	-31.91%
LONG-TERM LIABILITIES
Long-Term Debt	$20.00K	$16.07K	$0.00
YoY Change
Other Long-Term Liabilities	$1.210M	$1.210M
YoY Change
Total Long-Term Liabilities	$2.752M	$1.226M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.308M	$7.308M	$3.421M
Total Long-Term Liabilities	$2.752M	$1.226M	$0.00
Total Liabilities	$10.06M	$10.06M	$3.421M
YoY Change	194.07%	194.15%	-71.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$78.60M		-$65.26M
YoY Change	20.45%		14.76%
Common Stock	$101.3K		$76.57K
YoY Change	32.3%		3694.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$329.4K	-$329.4K	$6.087M
YoY Change
Total Liabilities & Shareholders Equity	$9.731M	$9.731M	$9.508M
YoY Change	2.34%	2.32%	576.0%

Cashflow Statement

Concept	2016 Q4	2016	2015 Q4
OPERATING ACTIVITIES
Net Income	-$3.700M	-$13.34M	-$2.690M
YoY Change	37.55%	59.08%	540.48%
Depreciation, Depletion And Amortization	$10.00K	$5.185K	$0.00
YoY Change		312.49%
Cash From Operating Activities	-$2.050M	-$8.413M	-$1.550M
YoY Change	32.26%	88.64%	252.27%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$160.8K	$0.00
YoY Change		-903.75%
Cash From Investing Activities	$0.00	$174.7K	$0.00
YoY Change		-973.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$3.769M
YoY Change		-73.27%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$3.498M	10.00K
YoY Change	-100.0%	-72.28%	-96.88%
NET CHANGE
Cash From Operating Activities	-2.050M	-$8.413M	-1.550M
Cash From Investing Activities	0.000	$174.7K	0.000
Cash From Financing Activities	0.000	$3.498M	10.00K
Net Change In Cash	-2.050M	-$4.740M	-1.540M
YoY Change	33.12%	-158.23%	1183.33%
FREE CASH FLOW
Cash From Operating Activities	-$2.050M	-$8.413M	-$1.550M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$2.050M	-$8.413M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	122395	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	9449114	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38040	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	45000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	20000	USD
CY2016Q4	us-gaap	Assets Assets	9730602	USD
CY2016	eyeg	Conversion Of Non Controlling Interests To Commonstock ConversionOfNonControllingInterestsToCommonstock	0	USD
CY2015	eyeg	Conversion Of Non Controlling Interests To Commonstock ConversionOfNonControllingInterestsToCommonstock	6818732	USD
CY2016	eyeg	Conversion Of Preferred Stock Into Common Stock ConversionOfPreferredStockIntoCommonStock	2776419	USD
CY2015	eyeg	Conversion Of Preferred Stock Into Common Stock ConversionOfPreferredStockIntoCommonStock	36408666	USD
CY2016	eyeg	Exercise Of Common Warrants ExerciseOfCommonWarrants	0	USD
CY2015	eyeg	Exercise Of Common Warrants ExerciseOfCommonWarrants	97	USD
CY2016	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2015	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	3532694	USD
CY2016	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	0	USD
CY2015	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	8222008	USD
CY2016	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	0	USD
CY2015	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	1148994	USD
CY2016	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	0	USD
CY2015	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	79930	USD
CY2016	us-gaap	Profit Loss ProfitLoss	-13343437	USD
CY2015	us-gaap	Profit Loss ProfitLoss	-8387972	USD
CY2016	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	0	USD
CY2015	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	-1663873	USD
CY2016	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2015	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	244111	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	510995	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	1224687	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-26287	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	95952	USD
CY2016	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-7703	USD
CY2015	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	2357	USD
CY2016	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	16727	USD
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1148	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	712795	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-148250	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1907500	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	450383	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	265754	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8413180	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4459169	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5185	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1257	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	4154038	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1412128	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	464981	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	417697	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1670930	USD
CY2016Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	16484	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1095738	USD
CY2015Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	25086	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7308058	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3420935	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	101309	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	76573	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	78106645	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	71209530	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-78598738	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65255301	USD
CY2016Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	58824	USD
CY2015Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	58824	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	120187	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	114788	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-329421	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	6086766	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9730602	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9507701	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1907500	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4225000	USD
CY2016Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	37349	USD
CY2015Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	907500	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	38587	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	55314	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Liabilities Liabilities	10060023	USD
CY2015Q4	us-gaap	Liabilities Liabilities	3420935	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1210000	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2015Q4	us-gaap	Assets Assets	9507701	USD
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-223172	USD
CY2016	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	323814	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	25000	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	20000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	149746	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-20000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	56206	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26826	USD
CY2015	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1479202	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3498227	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12616256	USD
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	6298	USD
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	90045	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	167001	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4758909	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8227132	USD
CY2016	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-3233636	USD
CY2015	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	907500	USD
CY2016	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	185746	USD
CY2015	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2016	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	1210000	USD
CY2015	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
CY2016	eyeg	Stock Issued For Acquisition StockIssuedForAcquisition	2909766	USD
CY2015	eyeg	Stock Issued For Acquisition StockIssuedForAcquisition	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3768698	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14101260	USD
CY2016	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	11000	USD
CY2015	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	0	USD
CY2016	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	31576	USD
CY2015	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5593563	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3960498	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8422542	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2717110	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	14016105	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	6677608	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	3684	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	947	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2016	us-gaap	Interest Expense InterestExpense	275	USD
CY2015	us-gaap	Interest Expense InterestExpense	1934493	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3409	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1710364	USD
CY2016	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2015	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	8222008	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13343437	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16615157	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.51
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.70
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8833898	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6164064	shares
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	5399	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	91211	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	USD
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-32967	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-27790	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13338038	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8268971	USD
CY2016	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5177	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-13338038	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-8296761	USD
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	669259	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2016	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	952184	USD
CY2015	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	477956	USD
CY2016	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	-13275986	USD
CY2015	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	-9075459	USD
CY2016	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-13275986	USD
CY2015	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-17302644	USD
CY2016Q3	us-gaap	Area Of Land AreaOfLand	2300	sqft
CY1999Q1	eyeg	License Expiration Period LicenseExpirationPeriod	P12Y
CY1999Q1	us-gaap	License Costs LicenseCosts	12500	USD
CY2016Q2	us-gaap	License Costs LicenseCosts	15000	USD
CY2013Q3	us-gaap	License Costs LicenseCosts	50000	USD
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	984000	USD
CY2016	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y5M5D
CY2016Q4	eyeg	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue	544000	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	758000	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	202000	USD
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	900000	USD
CY2015	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M17D
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	207000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	135000	USD
CY2016Q2	eyeg	Class Of Warrant Or Right Number Of Warrant Issued ClassOfWarrantOrRightNumberOfWarrantIssued	1742000	shares
CY2016Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1319289	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10130883	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7657287	shares
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1234000	shares
CY2016Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3400000	USD
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.50
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	9997223	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	668802	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	652609	USD
CY2016Q4	eyeg	Clinical Trials Currrent ClinicalTrialsCurrrent	770158	USD
CY2015Q4	eyeg	Clinical Trials Currrent ClinicalTrialsCurrrent	365277	USD
CY2016Q4	eyeg	Consulting Expenses Current ConsultingExpensesCurrent	44983	USD
CY2015Q4	eyeg	Consulting Expenses Current ConsultingExpensesCurrent	18500	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	174342	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	59352	USD
CY2016Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	12645	USD
CY2015Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	0	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3261040	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4362447	shares
CY2016Q4	eyeg	Money Market Funds Fair Value MoneyMarketFundsFairValue	1500882	USD
CY2016Q4	eyeg	Contingent Consideration Funds Fair Value ContingentConsiderationFundsFairValue	1210000	USD
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-46806801	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	780293	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6086766	USD
CY2015Q4	eyeg	Money Market Funds Fair Value MoneyMarketFundsFairValue	7200450	USD
CY2015Q4	eyeg	Contingent Consideration Funds Fair Value ContingentConsiderationFundsFairValue	0	USD
CY2016Q2	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	100000000	shares
CY2016	eyeg	Warrant Expiration Date WarrantExpirationDate	2021-12-30
CY2016Q4	eyeg	Goodwill And Inprocess Research And Development GoodwillAndInprocessResearchAndDevelopment	5438210	USD
CY2015Q4	eyeg	Goodwill And Inprocess Research And Development GoodwillAndInprocessResearchAndDevelopment	0	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1525896	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0	USD
CY2016Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	16069	USD
CY2015Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	0	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10130883	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7657287	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	444394	USD
CY2015	eyeg	Reclassification Of Previously Issued Warrant Liability To Stockholders Equity ReclassificationOfPreviouslyIssuedWarrantLiabilityToStockholdersEquity	79930	USD
CY2015	eyeg	Stock Issued During Period Value Conversion Of Convertible Securities1 StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1	-6818732	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	26826	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	1663873	USD
CY2015	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	3532694	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	36408666	USD
CY2016	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2015	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-32628	USD
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2751965	USD
CY2015Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2015	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	58244	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-1254338	USD
CY2015	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	10001760	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4099500	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1373858	USD
CY2015	eyeg	Stock Issued During Period Upon Exercise Of Warrants StockIssuedDuringPeriodUponExerciseOfWarrants	0	USD
CY2016	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <h1 style="TEXT-ALIGN: center; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 0pt; PADDING-RIGHT: 0pt; FONT: bold 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 9pt"> </h1> <h2 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> 1. Organization, Business</h2> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 20px; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">EyeGate Pharmaceuticals, Inc. (“EyeGate” or the “Company”) a Delaware corporation, began operations in December 2004 and is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate’s first product in clinical trials incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, EGP-437, that is delivered into the ocular tissues though our proprietary iontophoresis drug delivery system, the EyeGate® II Delivery System. The Company is developing the EyeGate® II Delivery System and EGP-437 combination product (together, the “EGP-437 Product”) for the treatment of various inflammatory conditions of the eye, including anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, post-cataract surgery inflammation and pain, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the retina. Effective March 7, 2016, the Company acquired all of the capital stock of Jade Therapeutics, Inc. (“Jade”), a privately-held company developing locally-administered, polymer-based products designed to treat poorly-served ophthalmic indications (the “Jade Acquisition”). <i>See</i> Note 13, “Acquisitions”. EyeGate and Jade are an integrated line of business developing ophthalmic solutions for a variety of ocular diseases and disorders.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 20px; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">On February 13, 2015, the Company completed an underwritten initial public offering (the “IPO”) for 683,250 shares of Common Stock. The net proceeds to the Company from the IPO, after deducting the underwriting discounts, commissions, and offering expenses, were approximately $2.7 million. Shares of the Company’s Common Stock began trading on the OTCQB Venture Marketplace under the symbol “EYEG” on February 13, 2015, and the IPO was closed on February 19, 2015. Immediately prior to the IPO, in related transactions, the Company converted all outstanding notes payable into shares of Common Stock, and all shares of its convertible preferred stock into shares of Common Stock. The various classes of shares of preferred stock were converted to shares of Common Stock at a different ratio for each class of preferred stock for 1.00 share of Common Stock. On August 5, 2015, the Company closed an underwritten follow-on public offering of 1,176,470 shares of its Common Stock, and warrants to purchase 1,176,470 shares of its Common Stock. The net proceeds to the Company from this follow-on offering, after deducting underwriting discounts, commissions, and offering expenses, were approximately $8.8 million. The warrants are immediately exercisable, and expire on August 5, 2020. At the closing of this follow-on offering, the Company also issued and sold additional warrants to purchase up to 176,470 shares of Common Stock in connection with the full exercise of the underwriters’ over-allotment option to purchase additional warrants. On June 30, 2016, the Company completed a subsequent registered direct offering of 441,000 shares of Common Stock and 2,776.5 shares of Series A Preferred Stock (convertible into 1,234,000 shares of Common Stock), along with a concurrent private placement of warrants to purchase Common Stock. The total net proceeds to the Company from this subsequent offering, after deducting the placement agent fees and offering expenses, were approximately $3.4 million. The warrants are initially exercisable on December 30, 2016, and expire on December 30, 2021. <i>See</i> Note 6, “Capital Stock”.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 20px; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">As of December 31, 2016, there were 10,130,883 shares of Common Stock outstanding, $0.01 par value, and no shares of Series A Preferred Stock outstanding, $0.01 par value.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 20px; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Effective July 31, 2015, the Company’s Common Stock began trading on the Nasdaq Capital Market under the symbol “EYEG”.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 20px; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Since its inception, EyeGate has devoted substantially all of its efforts to business planning, research and development, and raising capital.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 20px; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">The accompanying Consolidated Financial Statements have been prepared assuming that EyeGate will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. At December 31, 2016, EyeGate had Cash and Cash Equivalents of $3,635,224, and an Accumulated Deficit of $78,598,738. EyeGate has incurred losses and negative cash flows since inception, and future losses are anticipated. The Company anticipates having sufficient cash to fund planned operations for approximately five months, however, the acceleration or reduction of cash outflows by Company management can significantly impact the timing for raising additional capital to complete development of its products. To continue development, EyeGate will need to raise additional capital through equity financing, license agreements, and/or additional U.S. government grants. Although the Company successfully completed its IPO, a follow-on offering, and a registered direct offering, additional capital may not be available on terms favorable to EyeGate, if at all. On May 6, 2016, the SEC declared effective EyeGate’s registration statement on Form S-3, registering a total of $100,000,000 of its securities for sale to the public from time to time in what is known as a “shelf offering”. The Company does not know if any future offerings pursuant to its shelf registration statement will succeed. Accordingly, no assurances can be given that Company management will succeed in these endeavors. The Company’s recurring losses from operations have caused management to determine there is substantial doubt about the Company’s ability to continue as a going concern. The Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	preferred stock were converted to shares of Common Stock at a different ratio for each class of preferred stock for 1.00 share of Common Stock.
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	510995	USD
CY2016	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2909766	USD
CY2016	eyeg	Issuance Of Holdback Shares From Jade Acquisition Value IssuanceOfHoldbackSharesFromJadeAcquisitionValue	0	USD
CY2016	eyeg	Forfeiture Of Holdback Shares From Jade Acquisition Value ForfeitureOfHoldbackSharesFromJadeAcquisitionValue	0	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	668437	USD
CY2016	eyeg	Preferred Stock Issued During Period Value PreferredStockIssuedDuringPeriodValue	2776447	USD
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	56206	USD
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	5399	USD
CY2015	eyeg	Conversion Of Stock Conversion Price Per Share ConversionOfStockConversionPricePerShare	6.00
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18146381	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18050019	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1640669	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1226384	USD
CY2016Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6398050	USD
CY2015Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4452114	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	323832	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	164292	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	587	USD
CY2016Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	3478	USD
CY2015Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	137	USD
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 20px; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left"></div> <h4 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt"> Use of Estimates</h4> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 20px; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The Company makes significant estimates and assumptions in recording the accruals for our clinical trial and research activities, establishing the useful lives of intangible assets and property and equipment, and conducting impairment reviews of long-lived assets. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company monitors and regularly assesses these estimates, actual results could differ significantly from these estimates. The Company records changes in estimates in the period that it becomes aware of the change.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	42576	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	268093	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-329421	USD
CY2015	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2016	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2863	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0247	pure
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-13831191	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-8755011	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	487754	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	367038	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-13343437	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-8387973	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0013	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.00	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0184	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0627	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.1088	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3502	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2955	pure
CY2016	eyeg	Expiration Of State Net Operating Loss Carryforward Percent ExpirationOfStateNetOperatingLossCarryforwardPercent	-0.00	pure
CY2015	eyeg	Expiration Of State Net Operating Loss Carryforward Percent ExpirationOfStateNetOperatingLossCarryforwardPercent	-0.0003	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0295	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0043	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0143	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0024	pure
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges	17959	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4387806	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2179356	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	30900216	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26090848	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30900216	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26090848	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1525896	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4809000	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2478000	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	510995	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	1224687	USD
CY2016	eyeg	Operating Loss Carryforwards Expiration Period OperatingLossCarryforwardsExpirationPeriod	2036
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	vest 33% on the one-year anniversary of the grant date and the remainder ratably over a 24-month period
CY2015Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	4.20
CY2015Q4	eyeg	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue	1382000	USD

Files In Submission

Name	View Source	Status
0001144204-17-010635-index-headers.html	Edgar Link	pending
0001144204-17-010635-index.html	Edgar Link	pending
0001144204-17-010635.txt	Edgar Link	pending
0001144204-17-010635-xbrl.zip	Edgar Link	pending
eyeg-20161231.xml	Edgar Link	completed
eyeg-20161231.xsd	Edgar Link	pending
eyeg-20161231_cal.xml	Edgar Link	unprocessable
eyeg-20161231_def.xml	Edgar Link	unprocessable
eyeg-20161231_lab.xml	Edgar Link	unprocessable
eyeg-20161231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
line.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
spacer.gif	Edgar Link	pending
v459809_10k.htm	Edgar Link	pending
v459809_chrt-bar1.jpg	Edgar Link	pending
v459809_chrt-bar2.jpg	Edgar Link	pending
v459809_exh10x19.htm	Edgar Link	pending
v459809_exh21x1.htm	Edgar Link	pending
v459809_exh23x1.htm	Edgar Link	pending
v459809_exh31x1.htm	Edgar Link	pending
v459809_exh31x2.htm	Edgar Link	pending
v459809_exh32x1.htm	Edgar Link	pending
v459809_exh32x2.htm	Edgar Link	pending
v459809_image.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KPRX
KIORA PHARMACEUTICALS INC Stock $kprx

2016 Q4 Form 10-K Financial Statement

#000114420417010635 Filed on February 23, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KPRX KIORA PHARMACEUTICALS INC Stock $kprx

2016 Q4 Form 10-K Financial Statement

#000114420417010635 Filed on February 23, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KPRX
KIORA PHARMACEUTICALS INC Stock $kprx